Evidence map›Paper›PMID 39254902›Full record

ArticleJapanese journal of radiology2025

PRMT1 promotes radiotherapy resistance in glioma stem cells by inhibiting ferroptosis.

Hong Li, Xiaoyan Qi, Lijun He, Hao Yang, Haitao Ju

Abstract read
PubMed Publisher
In one paragraph

Article in Japanese journal of radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
  5. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Hong LiDepartment of Radiation Oncology, Peking University Cancer Hospital (Inner Mongolia Campus) and Affiliated Cancer Hospital of Inner Mongolia Medical University, Huhhot, 010020, Inner Mongolia Autonomous Region, China.
Xiaoyan QiDepartment of Medical Oncology, Peking University Cancer Hospital (Inner Mongolia Campus) and Affiliated Cancer Hospital of Inner Mongolia Medical University, Huhhot, 010020, Inner Mongolia Autonomous Region, China.
Lijun HeDepartment of Neurosurgery, Affiliated Hospital of Inner Mongolia Medical University, No. 1 Tongdao Street, Huimin District, Hohhot, 010020, Inner Mongolia, China.
Hao YangDepartment of Radiation Oncology, Peking University Cancer Hospital (Inner Mongolia Campus) and Affiliated Cancer Hospital of Inner Mongolia Medical University, Huhhot, 010020, Inner Mongolia Autonomous Region, China.
Haitao JuDepartment of Neurosurgery, Affiliated Hospital of Inner Mongolia Medical University, No. 1 Tongdao Street, Huimin District, Hohhot, 010020, Inner Mongolia, China. Juhaitao2023@163.com.

Funding

2021 Joint Project of Inner Mongolia Medical University YKDX2021LH003Natural Science Foundation Project of Inner Mongolia Autonomous Region 2020LH08042Young Science and Technology Talent Support Project of Universities in Inner Mongolia Autonomous Region NJYT24029
6 · The paper itself

Abstract

purposeThe existence of glioma stem cells (GSCs) in cancer is related to glioma radiotherapy resistance. In this research, the effect of protein arginine methyltransferase 1 (PRMT1) on the radiosensitivity of glioma stem cell (GSC)-like cells, as well as its underlying mechanism, was investigated.

methodsGSCs-like cells were analyzed and identified by flow cytometry. The self-renewal capability was evaluated by sphere-forming assay. The PRMT1 expression level in glioblastoma were analyzed using the Gene Expression Profiling Interactive Analysis database. The mRNA and protein were scrutinized by RT-qPCR and western blot, respectively. The radiosensitivity was evaluated by clonogenic survival assay. Ferroptosis was evaluated by detecting the levels of reactive oxygen species, malondialdehyde, Fe

resultsU87 and SHG44 cells with GSC-like phenotype (GSC-U87 and GSC-SHG44) displayed strong expression of CD133 and nestin versus the glioma cells. GSC-U87 and GSC-SHG44 possess the self-renewal capability. The level of PRMT1 was higher in glioblastoma tumor tissues than in the normal paracancer tissues. Knockdown of PRMT1 enhanced the radiotherapy sensitivity of GSCs-like cells, which was evidenced by reduced survival fraction in GSC-U87 and GSC-SHG44 underwent sh-PRMT1 transfection. But, this effect was attenuated by Fer-1 (a ferroptosis inhibitor) treatment, accompanied by the abatement of ferroptosis.

conclusionPRMT1 promoted radiotherapy resistance in GSCs-like cells by inhibiting ferroptosis.

Indexed as

Brain NeoplasmsFerroptosisGliomaNeoplastic Stem CellsProtein-Arginine N-MethyltransferasesRadiation ToleranceCell Line, TumorFlow CytometryHumansRepressor ProteinsPRMT1 protein, humanProtein-Arginine N-MethyltransferasesRepressor ProteinsFerroptosisGlioma stem cellsPRMT1Radiotherapy resistance

Identifiers

PMID39254902

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.